ALS Investment Fund is an institutional investor (Conventional VCs) founded in 2016 and headquartered in Boston, United States. Venture capital fund investing in biotech companies developing neurodegeneration drugs. The fund supports extraordinary people working to change the course of neurodegenerative diseases, particularly focusing on ALS. They aim to accelerate the development of a new generation of therapies that can dramatically improve the quality of life for patients by preserving cognition and motor function. The fund backs companies developing innovative drugs to transform neurodegenerative diseases into manageable conditions. This investment supports advancements in biotechnology and pharmaceutical research, with a strong emphasis on social impact by addressing a leading cause of death and disability.

Stage

Series A, Series B, Series A, Series B

Check size

$10M-$70M fund for 6-7 companies

HQ

Amsterdam, Netherlands

Founded

2016

Website

https://www.alsinvestmentfund.com/

LinkedIn

https://linkedin.com/company/alsinvestmentfund

What they look for

US/Europe focus; ALS/neurodegenerative disease therapies; strong founders, cutting-edge tech, platform approaches or multiple clinical drugs, proven basic science, entering clinical trials; modalities: small molecule, biologics, CRISPR, gene therapy, microbiome, protein-based, RNA therapeutics

Preparing to pitch ALS Investment Fund?

CrackTheDeck analyzes your pitch deck before the meeting — structure, narrative, investor fit.